Can Visceral Fat Injure Internal Organs?

Visceral fat can injure internal organs, and understanding how is essential for protecting long-term health. Unlike the subcutaneous fat you can pinch beneath the skin, visceral fat sits deep within the abdominal cavity, surrounding the liver, pancreas and intestines. It is highly metabolically active, releasing inflammatory compounds that drive chronic, low-grade inflammation throughout the body. This article explains how visceral fat differs from ordinary body fat, which organs are most at risk, what warning signs to look for, how to reduce visceral fat effectively, and when to seek medical advice.

How does visceral fat differ from ordinary body fat?

Visceral fat is stored deep within the abdominal cavity, surrounding major organs, and unlike subcutaneous fat it secretes pro-inflammatory cytokines and adipokines that drive systemic inflammation and metabolic harm.

Visceral fat is a metabolically active type of fat stored deep within the abdominal cavity, surrounding organs such as the liver, pancreas and intestines, and it behaves very differently from the subcutaneous fat that sits just beneath the skin. Subcutaneous fat, the kind you can pinch at the waist or thigh, acts largely as an energy reserve and provides some insulation. Visceral fat, by contrast, is embedded within the peritoneal cavity and is in close proximity to the portal circulation, meaning that substances it releases enter the liver directly.

What makes visceral fat particularly concerning from a clinical standpoint is its high metabolic activity. It secretes a range of signalling molecules known as adipokines, as well as pro-inflammatory cytokines such as interleukin-6 and tumour necrosis factor-alpha. These compounds promote a state of low-grade, chronic systemic inflammation that can affect tissues and organs throughout the body.

Unlike subcutaneous fat, visceral fat is not easily visible or measurable without specialist assessment. A person may appear to have a relatively normal body weight yet carry a significant burden of visceral fat, a pattern sometimes described as metabolically unhealthy normal weight. Waist circumference is a useful clinical proxy: NHS guidance suggests that a waist measurement above 94 cm in men and above 80 cm in women is associated with increased health risk, with substantially higher risk above 102 cm and 88 cm respectively.^[1] For some South Asian, Chinese, Japanese and other ethnic groups, risk thresholds are lower, and a GP can advise on what applies to you individually. Waist-to-height ratio (a ratio above 0.5 is generally considered a risk flag) is also increasingly recognised as a useful screening measure alongside waist circumference and BMI.

Waist circumference alone does not distinguish visceral from subcutaneous fat. MRI and CT scanning can provide a more precise assessment, but these are largely used in research and specialist settings rather than routine primary care; CT in particular involves ionising radiation and is not used simply to quantify fat.

Which organs are most at risk from excess visceral fat?

The liver, heart, pancreas and kidneys are most consistently at risk, with the liver particularly vulnerable due to direct portal drainage of fatty acids and inflammatory mediators from visceral fat.

Excess visceral fat is associated with increased risk of disease affecting several internal organs, with the liver, heart, pancreas and kidneys among those most consistently implicated in the research evidence. The liver is particularly vulnerable because visceral fat drains into the portal vein, exposing hepatic tissue to a continuous supply of free fatty acids and inflammatory mediators. This is associated with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease), which can progress through stages of inflammation and fibrosis to cirrhosis in some individuals.

The cardiovascular system is also significantly affected. Visceral fat is associated with raised levels of low-density lipoprotein (LDL) cholesterol and triglycerides, reduced high-density lipoprotein (HDL) cholesterol, arterial stiffness and hypertension. Central adiposity is recognised in UK cardiovascular risk assessment as a clinically relevant factor alongside overall body mass index (BMI).

The pancreas is at risk in two distinct ways. Fat can accumulate within pancreatic tissue itself, impairing beta-cell function and contributing to insulin resistance and type 2 diabetes. Visceral adiposity is also associated with an increased risk of acute pancreatitis, though the precise magnitude of risk varies across studies and the relationship should be understood as an association rather than a direct causal link.

The kidneys are also affected: visceral adiposity is associated with glomerular hyperfiltration, proteinuria and a higher risk of chronic kidney disease, including in people without established diabetes or hypertension, though the independence of this association from those conditions continues to be studied.^[23][24]

Emerging evidence, including data reviewed by Cancer Research UK, points to associations between excess body fat, particularly central adiposity, and colorectal cancer risk.^[8][9] Obstructive sleep apnoea is also more common in people with high visceral fat, where fat deposition around the upper airway and thorax compounds respiratory impairment. The breadth of organ involvement underlines why visceral fat is considered a central driver of cardiometabolic disease.

What are the warning signs that visceral fat may be affecting your health?

Warning signs include raised fasting glucose or HbA1c, elevated triglycerides with low HDL, raised liver enzymes, and hypertension, though many people have no symptoms in the early stages.

There is no single symptom that reliably signals excess visceral fat, but a cluster of clinical findings can indicate that visceral adiposity may already be affecting organ function. A progressively increasing waist circumference, particularly when accompanied by fatigue, raised blood pressure or abnormal blood glucose on routine testing, warrants further assessment. Many people with significant visceral fat accumulation have no symptoms at all in the early stages, which is why opportunistic screening during GP appointments is valuable.

The following findings on routine blood tests or clinical examination may suggest visceral fat is having a metabolic impact:

• Raised fasting glucose or HbA1c, indicating impaired insulin sensitivity or early type 2 diabetes

• Elevated triglycerides combined with low HDL cholesterol, a pattern consistent with metabolic syndrome

• Raised liver enzymes (ALT or AST), which may reflect hepatic steatosis; it is important to note that normal liver enzymes do not exclude MASLD, and an ultrasound scan may be considered if there is clinical concern^[12][13]

• Hypertension, particularly when difficult to control despite lifestyle measures

Symptoms that may prompt a person to seek advice include persistent fatigue, increased thirst or urinary frequency (suggestive of dysglycaemia), right upper abdominal discomfort (which can accompany fatty liver disease), and snoring or unrefreshing sleep (associated with sleep apnoea). Heartburn and acid reflux are also more common in people with central adiposity, as intra-abdominal pressure increases.

Seek urgent medical attention if you develop jaundice (yellowing of the skin or whites of the eyes), dark urine, severe right upper abdominal pain with fever, or vomiting blood or passing black stools. These are not typical features of visceral fat alone but are red flags for serious liver or gastrointestinal conditions that require prompt assessment.

It is important to note that the more common symptoms listed above are non-specific and can have many causes. Their presence does not confirm visceral fat-related organ injury, but they do provide a reasonable basis for a GP consultation and targeted investigation.

How can you reduce visceral fat and protect your organs?

A sustained calorie deficit through dietary change and at least 150 minutes of moderate aerobic activity per week are the most evidence-based approaches, with NICE-approved medications available for eligible individuals.

Visceral fat tends to respond well to lifestyle intervention, and even modest reductions in body weight, in the range of 5 to 10 per cent, are associated with measurable improvements in metabolic markers and organ health.^[20] A sustained calorie deficit achieved through dietary change remains the most evidence-based approach. Diets that reduce refined carbohydrates and ultra-processed foods, while emphasising vegetables, wholegrains, lean protein and unsaturated fats, are broadly consistent with NHS Eatwell Guide principles and can support weight loss and a reduction in visceral fat.

Physical activity is independently beneficial, even without significant weight loss. Both aerobic exercise (such as brisk walking, cycling or swimming) and resistance training are associated with reductions in visceral fat.^[18][19] The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week for adults, alongside muscle-strengthening activities on two or more days.^[15][16] Reducing prolonged sedentary time also contributes to metabolic health.

For people who have not achieved sufficient benefit from lifestyle measures alone, NICE technology appraisals have recommended certain pharmacological treatments for weight management in eligible individuals. These include GLP-1 receptor agonists such as semaglutide (Wegovy, NICE TA875) and the dual GIP and GLP-1 receptor agonist tirzepatide (Mounjaro, NICE TA1026), which is authorised by the MHRA for both type 2 diabetes and chronic weight management.^[28][29] Access to these medicines on the NHS depends on national commissioning decisions and local ICB pathways, and they are typically prescribed through specialist weight management services. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where tirzepatide or semaglutide may be one option a prescriber considers if clinically appropriate. Bariatric surgery remains an option for people with severe obesity where other interventions have not been effective, subject to NICE criteria and local ICB commissioning decisions.

Addressing other modifiable risk factors, including smoking cessation, limiting alcohol intake and managing sleep quality, further supports organ protection alongside visceral fat reduction.

When should you speak to a GP about visceral fat?

Speak to a GP if your waist circumference exceeds NHS thresholds, or if you notice fatigue, raised blood pressure, abdominal discomfort or unrefreshing sleep that may indicate metabolic impact.

You should speak to a GP about visceral fat if your waist circumference exceeds the NHS thresholds of 94 cm for men or 80 cm in women, particularly if you also have other risk factors such as a family history of type 2 diabetes, cardiovascular disease or fatty liver disease. People from South Asian, Chinese, Japanese and some other ethnic backgrounds may face increased risk at lower waist measurements, and a GP can advise on the thresholds relevant to you.^[7][1] A GP can arrange relevant blood tests, including fasting glucose, HbA1c, a full lipid profile and liver function tests, to assess whether visceral fat is already affecting your metabolic health.

Seek a GP appointment promptly if you notice any of the following:

• Unexplained fatigue or increased thirst, which may indicate early dysglycaemia

• Persistent right upper abdominal discomfort, which can be associated with hepatic steatosis

• Blood pressure readings consistently above 135/85 mmHg when measured at home (per NICE NG136; a clinic reading above 140/90 mmHg is the equivalent threshold in a clinical setting)^[10][11]

• Unrefreshing sleep or witnessed pauses in breathing, which may suggest obstructive sleep apnoea

• Rapid, unintentional weight gain around the abdomen, especially after a period of reduced activity or significant stress

If you experience chest pain, sudden breathlessness, jaundice, severe abdominal pain with fever, vomiting blood or passing black stools, these are potential emergencies and you should call 999 or attend an accident and emergency department immediately. For urgent advice that does not require an emergency response, NHS 111 is available around the clock.

Your GP can also refer you to structured weight management services, dietetic support or specialist clinics where appropriate. If you are prescribed any medication for weight management or a related condition and experience unexpected side effects, these can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Early engagement with your GP is the most effective way to prevent visceral fat from causing lasting organ damage.

Scientific References

1. Calculate your waist to height ratio.
2. AA in Obesity and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Nonalcoholic Fatty Liver Disease (NAFLD).
3. Crosstalk between visceral adipose tissue secretome and tumoral microenvironment in obesity-induced colorectal cancer.
4. Male Obesity and Cardiometabolic Risk: Inflammatory Mechanisms and Clinical Implications.
5. The immunogenic cross-talk in pediatric MASLD: does subclinical immune dysfunction accelerate early hepatic destruction?.
6. Cardiometabolic risk reduction with digital twinning in patients with type 2 diabetes.
7. Body roundness index (BRI) and obesity-related anthropometrics: Relationship to visceral adiposity, insulin sensitivity index and cardiometabolic risk.
8. Colorectal Cancer and Central Obesity.
9. Visceral adipose tissue and the risk of colorectal adenomas: a meta-analysis of observational studies.
10. Hypertension in adults: diagnosis and management (NG136) – Recommendations.
11. NG136 Hypertension in adults: Visual summary.
12. Identifying MASLD Patients with MASH or Significant Fibrosis: The Role of Lower ALT Thresholds.
13. The Relationships Between Diet Quality Index, Appendicular Skeletal Muscle Mass, and Metabolic Syndrome in a Population with Metabolic Dysfunction-Associated Steatotic Liver Disease.
14. Clinical and biochemical phenotypes of Lean MAFLD: machine learning-based biomarker identification and statistical association analysis.
15. Physical activity guidelines: UK Chief Medical Officers' report.
16. UK Chief Medical Officers' physical activity guidelines (full guidance text).
17. Physical activity guidelines for adults aged 19 to 64.
18. Aerobic Exercise and Weight Loss in Adults (dose-response meta-analysis of 116 RCTs).
19. The Effect of Resistance Training in Healthy Adults on Body Fat: systematic review and meta-analysis.
20. Lifestyle-Induced Visceral Fat Loss as a Key Target for Durable Cardiometabolic Health: MRI-Assessed 5- and 10-Year Follow-Up After 2 Clinical Trials.
21. Effects of concurrent training on fat mass and its distribution in individuals with overweight or obesity: a systematic review, meta-analysis, and exploratory regression analysis.
22. Comparative Efficacy of Exercise Type on Visceral Adipose Tissue in Patients With Prediabetes and Type 2 Diabetes Mellitus: A Systematic Review With Pairwise and Network Meta-Analyses.
23. The Vicious Link Between Visceral Fat, Proteinuria, and Kidney Disease.
24. Mechanisms of Obesity-Related Kidney Disease: From Adipose Depot Biology to the Chymase-Aldosterone and Ghrelin-Leptin Axes.
25. Obesity, kidney dysfunction, and inflammation: interactions in hypertension.
26. Obesity and synergistic risk factors for chronic kidney disease in African American adults: the Jackson Heart Study.
27. Semaglutide for managing overweight and obesity (TA875).
28. Tirzepatide for managing overweight and obesity (TA1026).
29. MHRA authorises diabetes drug Mounjaro (tirzepatide) for weight management and weight loss.
30. Tirzepatide for treating type 2 diabetes (TA924).
31. Mounjaro (tirzepatide) EPAR – Product Information.

Frequently Asked Questions